Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

General Research Article

Association Serum S100B Protein in Alzheimer’s Disease: A Case Control Study from South India

Author(s): Jaydip R. Chaudhuri, Kandadai R. Mridula, Chikkirala Rathnakishore, Alluri Anamika, Naveen R. Samala, Banda Balaraju and VCS Srinivasarao Bandaru*

Volume 17 , Issue 12 , 2020

Page: [1095 - 1101] Pages: 7

DOI: 10.2174/1567205018666210119145104

Price: $65

Abstract

Background: Recent evidence points to a possible link between the inflammatory modulatory protein S100B protein and the pathogenesis of Alzheimer’s disease (AD).

Objective: To investigate the elevated levels of serum S100B protein among AD in a South Indian cohort and its correlation with severity of cognitive impairment.

Methods: A cross-sectional study was conducted with 100 AD patients and 100 age and sex matched healthy controls. Diagnosis of AD was made by a qualified neurologist using NINCDS ADRDA criteria. Measurement of serum S100B protein was performed using solid phase sandwich ELISA method in both cases and controls.

Results: Significantly higher prevalence of elevated serum S100B protein 44(44%) (p<0.0001), hypertension 52(52%) (p=0.02), diabetes mellitus 58(58%) (p=0.002), thyroid dysfunction 28(28%) (p=0.009), positive CRP 46(46%) (p<0.0001) and lower mean Mini-Mental State Examination (MMSE) values 20.4±5.1 (p<0.0001) were seen in AD patients compared to controls. Elevated S100B protein levels were significantly associated with Clinical dementia rating (CDR) score 2(34%) (p=0,05) and score 3 (61.3%) (p=0.03) compared to normal levels. After multivariable logistic regression analysis positive C-Reactive Protein (odds: 3.2; 95%CI: 2.8-9.8)(p=0.001), elevated S100B protein (odds: 9.0;95%CI:2.2-35.8) and diabetes mellitus (odd:1.2;95%CI:1.0-4.9)(p<0.0001), were significantly associated with AD.

Conclusion: In our study, we established an independent association of elevated serum S100B protein levels with AD. Elevated S100B protein levels higher in CDR score 3.

Keywords: Alzheimer's disease, elevated serum S100B protein, CRP, case control study, diabetes mellitus, neurodegeneration.

[1]
Chaves ML, Camozzato AL, Ferreira ED, et al. Serum levels of S100B and NSE proteins in Alzheimer’s disease patients. J Neuroinflammation 2010; 7: 6.
[http://dx.doi.org/10.1186/1742-2094-7-6] [PMID: 20105309]
[3]
Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ, Medeiros R. Inflammation: The link between comorbidities, genetics, and Alzheimer’s disease. J Neuroinflammation 2018; 15(1): 276.
[http://dx.doi.org/10.1186/s12974-018-1313-3] [PMID: 30249283]
[4]
Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer’s disease. Nat Rev Immunol 2006; 6(5): 404-16.
[http://dx.doi.org/10.1038/nri1843] [PMID: 16639431]
[5]
Cristóvão JS, Gomes CM. S100 proteins in Alzheimer’s disease. Front Neurosci 2019; 13: 463.
[http://dx.doi.org/10.3389/fnins.2019.00463] [PMID: 31156365]
[6]
Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999; 1450(3): 191-231.
[http://dx.doi.org/10.1016/S0167-4889(99)00058-0] [PMID: 10395934]
[7]
Leclerc E, Sturchler E, Vetter SW. The S100B/RAGE axis in Alzheimer’s disease. Cardiovasc Psychiatry Neurol 2010; 2010539581
[http://dx.doi.org/10.1155/2010/539581] [PMID: 20672051]
[8]
Ben Abdesselam O, Vally J, Adem C, Foglietti MJ, Beaudeux JL. Reference values for serum S-100B protein depend on the race of individuals. Clin Chem 2003; 49(5): 836-7.
[http://dx.doi.org/10.1373/49.5.836] [PMID: 12709387]
[9]
Konukoglu D, Fırtına S, Erkol G, Bolayırlı IM. Comparing oxidative stress markers and S100B, Aβ40 proteins as independent neurological markers in distinguishing the relation of Alzheimer’s disease and diabetes mellitus. J Neurol Neurosci 2016; 7: 5.
[http://dx.doi.org/10.21767/2171-6625.1000146]
[10]
Thelin EP, Nelson DW, Bellander BM. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir (Wien) 2017; 159(2): 209-25.
[http://dx.doi.org/10.1007/s00701-016-3046-3] [PMID: 27957604]
[12]
Bandarua VCSS, Chaudhury RC, Lalitha L, et al. Prevalence of asymptomatic nonalcoholic fatty liver disease in nondiabetic participants: A study from south India. Egypt J Intern Med 2019; 31: 92-8.
[http://dx.doi.org/10.4103/ejim.ejim_76_18]
[13]
Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86(19): 7611-5.
[http://dx.doi.org/10.1073/pnas.86.19.7611] [PMID: 2529544]
[14]
Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett 1997; 235(1-2): 5-8.
[http://dx.doi.org/10.1016/S0304-3940(97)00701-5] [PMID: 9389582]
[15]
Lavado LK, Zhang MH, Patel K, Khan S, Patel UK. Biometals as potential predictors of the neurodegenerative decline in Alzheimer’s disease. Cureus 2019; 11(9)e5573
[http://dx.doi.org/10.7759/cureus.5573] [PMID: 31695992]
[16]
Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D. The association between blood pressure and incident Alzheimer disease: A systematic review and meta-analysis. Epidemiology 2011; 22(5): 646-59.
[http://dx.doi.org/10.1097/EDE.0b013e31822708b5] [PMID: 21705906]
[17]
Joas E, Bäckman K, Gustafson D, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012; 59(4): 796-801.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.182204] [PMID: 22331381]
[18]
Yasar S, Xia J, Yao W, et al. Ginkgo Evaluation of Memory (GEM) Study Investigators. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo evaluation of memory study. Neurology 2013; 81(10): 896-903.
[http://dx.doi.org/10.1212/WNL.0b013e3182a35228] [PMID: 23911756]
[19]
Østergaard SD, Mukherjee S, Sharp SJ, et al. Alzheimer’s Disease Genetics Consortium. GERAD1 Consortium; EPIC-InterAct Consortium. Associations between potentially modifiable risk factors and alzheimer disease: A mendelian randomization study. PLoS Med 2015; 12(6)e1001841
[http://dx.doi.org/10.1371/journal.pmed.1001841] [PMID: 26079503]
[20]
Dos Santos Matioli MNP, Suemoto CK, Rodriguez RD, et al. Diabetes is not associated with Alzheimer’s disease neuropathology. J Alzheimers Dis 2017; 60(3): 1035-43.
[http://dx.doi.org/10.3233/JAD-170179] [PMID: 28984587]
[21]
Wang KC, Woung LC, Tsai MT, Liu CC, Su YH, Li CY. Risk of Alzheimer’s disease in relation to diabetes: A population-based cohort study. Neuroepidemiology 2012; 38(4): 237-44.
[http://dx.doi.org/10.1159/000337428] [PMID: 22572745]
[22]
Bongarzone S, Savickas V, Luzi F, Gee AD. Targeting the receptor for advanced glycation endproducts (RAGE): A medicinal chemistry perspective. J Med Chem 2017; 60(17): 7213-32.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00058] [PMID: 28482155]
[23]
Tan ZS, Vasan RS. Thyroid function and Alzheimer’s disease. J Alzheimers Dis 2009; 16(3): 503-7.
[http://dx.doi.org/10.3233/JAD-2009-0991] [PMID: 19276542]
[24]
Kheirouri S, Ebrahimi E, Alizadeh M. Association of S100B serum levels with metabolic syndrome and its components. Acta Med Port 2018; 31(4): 201-6.
[http://dx.doi.org/10.20344/amp.9073] [PMID: 29855413]
[25]
Gonçalves CA, Leite MC, Guerra MC. Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol 2010; 2010790431
[http://dx.doi.org/10.1155/2010/790431] [PMID: 20672003]
[26]
Zhang Y, Reichel JM, Han C, Zuniga-Hertz JP, Cai D. Astrocytic process plasticity and IKKβ/NF-κB in central control of blood glucose, blood pressure, and body weight. Cell Metab 2017; 25(5): 1091-1102.e4.
[http://dx.doi.org/10.1016/j.cmet.2017.04.002] [PMID: 28467927]
[27]
Forti P, Olivelli V, Rietti E, et al. Serum thyroid-stimulating hormone as a predictor of cognitive impairment in an elderly cohort. Gerontology 2012; 58(1): 41-9.
[http://dx.doi.org/10.1159/000324522] [PMID: 21430364]
[28]
Hu Y, Wang ZC, Guo QH, Cheng W, Chen YW. Is thyroid status associated with cognitive impairment in elderly patients in China? BMC Endocr Disord 2016; 16: 11.
[http://dx.doi.org/10.1186/s12902-016-0092-z] [PMID: 26897535]
[29]
Kim H, Shin A, Lee KJ. Differences in C-reactive protein level in patients with Alzheimer’s disease and mild cognitive impairment. J Psychiatry 2015; 18: 1.
[30]
Song IU, Chung SW, Kim YD, Maeng LS. Relationship between the hs-CRP as non-specific biomarker and Alzheimer’s disease according to aging process. Int J Med Sci 2015; 12(8): 613-7.
[http://dx.doi.org/10.7150/ijms.12742] [PMID: 26283879]
[31]
Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009; 5(4): 318-23.
[http://dx.doi.org/10.1016/j.jalz.2009.04.1230] [PMID: 19560102]
[32]
Serpente M, Bonsi R, Scarpini E, Galimberti D. Innate immune system and inflammation in Alzheimer’s disease: From pathogenesis to treatment. Neuroimmunomodulation 2014; 21(2-3): 79-87.
[http://dx.doi.org/10.1159/000356529] [PMID: 24557039]
[33]
Liu L, Chan C. The role of inflammasome in Alzheimer’s disease. Ageing Res Rev 2014; 15: 6-15.
[http://dx.doi.org/10.1016/j.arr.2013.12.007] [PMID: 24561250]
[34]
Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. European Alzheimer’s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer’s Disease; Alzheimer’s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 2013; 45(12): 1452-8.
[http://dx.doi.org/10.1038/ng.2802] [PMID: 24162737]
[35]
Yarchoan M, Louneva N, Xie SX, et al. Association of plasma C-reactive protein levels with the diagnosis of Alzheimer’s disease. J Neurol Sci 2013; 333(1-2): 9-12.
[http://dx.doi.org/10.1016/j.jns.2013.05.028] [PMID: 23978419]
[36]
Arevalo-Rodriguez I, Smailagic N, Roqué I, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2015; 3(3)CD010783
[PMID: 25740785]
[37]
Whitaker-Azmitia PM, Wingate M, Borella A, Gerlai R, Roder J, Azmitia EC. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: Implications for Alzheimer’s disease and Down’s syndrome. Brain Res 1997; 776(1-2): 51-60.
[http://dx.doi.org/10.1016/S0006-8993(97)01002-0] [PMID: 9439795]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy